PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.46
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
No Data
No Data available this quarter, please select a different quarter.
6.50
P/B 1.1-1.25x AGEN's 5.45. Bill Ackman would demand evidence of superior asset utilization.
-35.87
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-36.06
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
6.50
Fair value ratio 1.1-1.25x AGEN's 5.45. Bill Ackman would demand evidence of superior economics.
-4.58%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-2.79%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.